← All trials
NCT04371393
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2020
- Primary completion
- Apr 30, 2021
- Completion date
- Apr 30, 2022
- First posted
- May 1, 2020
- Last posted
- May 22, 2020
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Baylor UniversityStudy director
- Duke UniversityStudy director
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiReponsible party - principal investigator
- Mesoblast, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.